Kåre Schultz

2018

In 2018, Kåre Schultz earned a total compensation of $32.5M as President and Chief Executive Officer at Teva Pharmaceutical Industries, a 91% increase compared to previous year.

Compensation breakdown

Bonus$20,000,000
Non-Equity Incentive Plan$3,790,360
Option Awards$1,500,019
Salary$2,000,000
Stock Awards$4,499,977
Other$679,519
Total$32,469,875

Schultz received $20M in bonus, accounting for 61.60% of the total pay in 2018.

Schultz also received $3.8M in non-equity incentive plan, $1.5M in option awards, $2M in salary, $4.5M in stock awards and $679.5K in other compensation.

Rankings

In 2018, Kåre Schultz's compensation ranked 45th out of 11,645 executives tracked by ExecPay. In other words, Schultz earned more than 99.6% of executives.

ClassificationRankingPercentile
All
45
out of 11,645
100th
Division
Manufacturing
10
out of 4,769
100th
Major group
Chemicals And Allied Products
4
out of 1,698
100th
Industry group
Drugs
2
out of 1,434
100th
Industry
Pharmaceutical Preparations
1
out of 1,092
100th
Source: SEC filing on April 16, 2019.

Schultz's colleagues

We found four more compensation records of executives who worked with Kåre Schultz at Teva Pharmaceutical Industries in 2018.

2018

Carlo de Notaristefani

Teva Pharmaceutical Industries

Executive Vice President, Global Operations

2018

Hafrun Fridriksdottir

Teva Pharmaceutical Industries

Executive Vice President, Global Research and Development

2018

Mark Sabag

Teva Pharmaceutical Industries

Executive Vice President, Global Human Resources

2018

Michael McClellan

Teva Pharmaceutical Industries

Chief Financial Officer

News

You may also like